Effect of intestinal resection on quality of life in Crohn's disease
Date
2015
Authors
Wright, E.
Kamm, M.
De Cruz, P.
Hamilton, A.
Ritchie, K.
Krejany, E.
Gorelik, A.
Liew, D.
Prideaux, L.
Lawrance, I.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Crohn's and Colitis, 2015; 9(6):452-462
Statement of Responsibility
Emily K. Wright, Michael A. Kamm, Peter De Cruz, Amy L. Hamilton, Kathryn J. Ritchie, Efrosinia O. Krejany, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C. Lawrance, Jane M. Andrews, Peter A. Bampton, Miles P. Sparrow, Timothy H. Florin, Peter R. Gibson, Henry Debinski, Richard B. Gearry, Finlay A. Macrae, Rupert W. Leong, Ian Kronborg, Graeme Radford-Smith, Warwick Selby, Michael J. Johnston, Rodney Woods, P. Ross Elliott, Sally J. Bell, Steven J. Brown, William R. Connell, Paul V. Desmond
Conference Name
Abstract
Introduction: Patients with Crohn’s disease have poorer health-related quality of life [HRQoL] than healthy individuals, even when in remission. Although HRQoL improves in patients who achieve drug-induced or surgically induced remission, the effects of surgery overall have not been well characterised. Methods: In a randomised trial, patients undergoing intestinal resection of all macroscopically diseased bowel were treated with postoperative drug therapy to prevent disease recurrence. All patients were followed prospectively for 18 months. C-reactive protein [CRP], Crohn’s Disease Activity Index [CDAI], and faecal calprotectin [FC] were measured preoperatively and at 6, 12, and 18 months. HRQoL was assessed with a general [SF36] and disease-specific [IBDQ] questionnaires at the same time points. Results: A total of 174 patients were included. HRQoL was poor preoperatively but improved significantly [p < 0.001] at 6 months postoperatively. This improvement was sustained at 18 months. Females and smokers had a poorer HRQoL when compared with males and non-smokers, respectively. Persistent endoscopic remission, intensification of drug treatment at 6 months, and anti-tumour necrosis factor therapy were not associated with HRQoL outcomes different from those when these factors were not present. There was a significant inverse correlation between CDAI, [but not endoscopic recurrence, CRP, or FC] on HRQoL. Conclusion: Intestinal resection of all macroscopic Crohn’s disease in patients treated with postoperative prophylactic drug therapy is associated with significant and sustained improvement in HRQoL irrespective of type of drug treatment or endoscopic recurrence. HRQoL is lower in female patients and smokers. A higher CDAI, but not direct measures of active disease or type of drug therapy, is associated with a lower HRQoL.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). All rights reserved.